Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

Image Credit: ACROBiosystems The biological and immunological functions of B-lymphocytes, monocytes, dendritic cells, and fibroblasts are all affected by the cytokines IL-4 and IL-13. These ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

Here we demonstrate that AIDS-KS cells express surface interleukin-4 (IL-4) receptors, and that IL-4 toxin (IL-4(38-37)-PE38KDEL) is specifically cytotoxic to these cells. Intratumoral ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

In addition, various cytokines and growth factors produced by these cells, such as interleukin (IL)-4 (Leonard et al, 1997; Shi et al, 1998a), IL-5 (Shi et al, 1998b; Till et al, 1998), IL-10 ...

This pathway is inhibited by interferon-γ and interleukin-4. The transcription factor (T-bet, ROR-γt, or GATA3) characteristic of each pathway is shown. R denotes receptor. Interleukin-23 can ...

To the Editor: In 1997, Hershey et al. reported finding a mutation in the interleukin-4 receptor α allele in 13 of 20 patients with atopy, as compared with 5 of 30 control subjects. 1 This ...